Medico Remedies Analyst Review May 2026
- May 22, 2026
- Posted by: Neeraj Pandey
- Category: News
This Medico Remedies analyst review for May 2026 covers the key data investors need for MEDICOREME at its current price of Rs 145. Medico Remedies (NSE: MEDICOREME) is a pharmaceutical company with a market capitalisation of approximately Rs 250 crore, manufacturing generic formulations for domestic and export markets. The analyst consensus target of Rs 188 implies meaningful upside, and this Medico Remedies analyst review examines technical levels, business performance, valuation, and key risks for MEDICOREME through FY27.
Click Here – Get Free Investment Predictions
Medico Remedies Company Snapshot May 2026
Medico Remedies produces tablets, capsules, and liquid formulations across cardiovascular, anti-infective, and gastrointestinal therapy areas for domestic hospital and retail distribution. The table below summarises the key data referenced in this Medico Remedies analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | MEDICOREME |
| Sector | Pharmaceuticals – Generic Formulations |
| CMP (May 2026) | Rs 145 |
| 52 Week High | Rs 238 |
| 52 Week Low | Rs 108 |
| Market Cap | Rs 250 Crore |
| Trailing P/E | 18x |
| Analyst Consensus Target | Rs 188 |
| Bull Case Target | Rs 235 |
| Bear Case Target | Rs 128 |
Analyst Insight in This Medico Remedies Analyst Review
Associate Director Kunal Singla suggests watching Medico Remedies closely in May 2026. At Rs 145, Kunal Singla flags Pharmaceuticals – Generic Formulations sector dynamics as the primary driver for MEDICOREME’s near-term price action. He notes support in the Rs 110.16 to Rs 137.75 zone and flags a sustained close above Rs 153.70 as a positive signal. Kunal Singla’s perspective adds professional analysis to this Medico Remedies analyst review and is not a buy recommendation.
Technical Analysis in This Medico Remedies Analyst Review
At Rs 145, MEDICOREME is trading within its 52-week band of Rs 108 to Rs 238. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 110.16 to Rs 137.75 band while resistance is seen in the Rs 153.70 to Rs 166.50 zone. A sustained move above Rs 153.70 could open the path toward the analyst consensus target of Rs 188 as identified in this Medico Remedies analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 110.16 to Rs 137.75 – investors tracking this Medico Remedies analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for MEDICOREME.
- Resistance Zone: Rs 153.70 to Rs 166.50 – a sustained close above Rs 153.70 would be a positive breakout signal worth flagging in this Medico Remedies analyst review.
- Medium-Term Target: The analyst consensus of Rs 188 represents the base-case upside scenario in this Medico Remedies analyst review.
Business Segment Analysis
Generic Formulations (Tablets, Capsules, Liquids)
This is the primary revenue and margin driver for Medico Remedies, directly supporting the earnings trajectory toward the consensus target of Rs 188.
Domestic Branded Generic Sales
This segment adds scale and diversification to Medico Remedies’s business model and is a meaningful EPS contributor through FY27 and FY28.
Export of Generic Medicines
This represents the medium-term growth frontier for Medico Remedies and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Medico Remedies Analyst Review
At Rs 145, Medico Remedies trades at a trailing P/E of 18x. This Medico Remedies analyst review presents three scenarios: a bull case of Rs 235 on strong earnings delivery, a base case of Rs 188 at analyst consensus, and a bear case of Rs 128 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Medico Remedies analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 235 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 188 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 128 | Earnings miss or macro headwinds |
Trade Outlook for Medico Remedies
Based on the technical and fundamental analysis in this Medico Remedies analyst review, investors might watch MEDICOREME near the support zone of Rs 110.16 to Rs 137.75 for potential opportunities. A flag above Rs 153.70 could suggest improving momentum toward Rs 188. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Medico Remedies in FY27
A well-rounded Medico Remedies analyst review must assess downside risks. Key risks for Medico Remedies include a macro slowdown affecting Pharmaceuticals – Generic Formulations sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in MEDICOREME.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Medico Remedies Analyst Review Verdict for 2026
This Medico Remedies analyst review concludes that at Rs 145, MEDICOREME offers a defined risk-reward with a consensus target of Rs 188. The 52-week range of Rs 108 to Rs 238 provides context on the current entry point. Use this Medico Remedies analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on MEDICOREME.
Frequently Asked Questions: Medico Remedies Analyst Review 2026
What is the analyst target for Medico Remedies in 2026?
The analyst consensus target is Rs 188, with a bull case of Rs 235 and a bear case of Rs 128. This Medico Remedies analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is Medico Remedies a good investment at Rs 145?
At Rs 145 with a P/E of 18x and a consensus target of Rs 188, this Medico Remedies analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Generic Formulations sector. Always consult a SEBI-registered advisor before investing.
What is Medico Remedies’s 52-week high and low?
The 52-week high is Rs 238 and the 52-week low is Rs 108. At Rs 145, MEDICOREME is positioned within this range as noted in this Medico Remedies analyst review.
What are the key risks for Medico Remedies?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Generic Formulations sector as assessed in this Medico Remedies analyst review.
Where can I track live data for Medico Remedies?
Track Medico Remedies’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Medico Remedies analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
